Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?
Department of Physiology and Pharmacology, Sapienza—University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
Molecules 2016, 21(9), 1243; https://doi.org/10.3390/molecules21091243
Received: 26 July 2016 / Accepted: 12 September 2016 / Published: 17 September 2016
(This article belongs to the Special Issue Potential Neuromodulatory Profile of Phytocompounds in Brain Disorders)
A growing body of in vitro and in vivo evidences shows a possible role of polyphenols in counteracting neurodegeneration: curcumin and resveratrol are attractive substances in this regard. In fact, epidemiological studies highlight a neuroprotective effect of turmeric (rhizome of Curcuma longa L.), the main source of curcumin. Moreover, the consumption of red wine, the main source of resveratrol, has been related to a lower risk of developing dementia. In this review, we analyzed the published clinical trials investigating curcumin and resveratrol in the prevention or treatment of cognitive disorders. The ongoing studies were also described, in order to give an overview of the current search on this topic. The results of published trials (five for curcumin, six for resveratrol) are disappointing and do not allow to draw conclusions about the therapeutic or neuroprotective potential of curcumin and resveratrol. These compounds, being capable of interfering with several processes implicated in the early stages of dementia, could be useful in preventing or in slowing down the pathology. To this aim, an early diagnosis using peripheral biomarkers becomes necessary. Furthermore, the potential preventive activity of curcumin and resveratrol should be evaluated in long-term exposure clinical trials, using preparations with high bioavailability and that are well standardized.
View Full-Text
Keywords:
polyphenols; curcumin; turmeric; resveratrol; grape wine; dementia; Alzheimer; cognitive disorders; clinical trials
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Mazzanti, G.; Di Giacomo, S. Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence? Molecules 2016, 21, 1243. https://doi.org/10.3390/molecules21091243
AMA Style
Mazzanti G, Di Giacomo S. Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence? Molecules. 2016; 21(9):1243. https://doi.org/10.3390/molecules21091243
Chicago/Turabian StyleMazzanti, Gabriela; Di Giacomo, Silvia. 2016. "Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?" Molecules 21, no. 9: 1243. https://doi.org/10.3390/molecules21091243
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit